Drug Profile
Dalcinonacog alfa - GC biopharma
Alternative Names: CB-2679d; CB-FIX; DalcA; Dalcinonacog alfa - Gyre Therapeutics/ISU Abxis; Factor IX - Gyre Therapeutics ; FIX-NG; ISU-304Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Catalyst Biosciences
- Developer Gyre Therapeutics; ISU Abxis
- Class Antihaemorrhagics; Blood coagulation factors; Peptide hydrolases; Recombinant proteins
- Mechanism of Action Factor IX replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haemophilia
Highest Development Phases
- Phase II Haemophilia B
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 27 Feb 2023 GC Biopharma acquires Dalcinonacog alfa from Catalyst Bioscience
- 14 Nov 2022 Phase-II development for Haemophilia B (In adolescents, In children, Treatment-experienced, In adults) is still ongoing in South Africa (IV)